Lindsey Shapiro, PhD,  science writer—

KVD900, KalVista Pharmaceuticals’ investigational on-demand treatment for swelling attacks in people with hereditary angioedema (HAE), will now be called sebetralstat, the company announced. Sebetralstat will become the nonproprietary nomenclature for the treatment’s active ingredients, meaning that will be the generic name for any medication using the same formulation…

Takhzyro (lanadelumab) led to significant benefits for patients with hereditary angiodema (HAE) in France who received the therapy as part of an early-access program prior to its approval in Europe, a study has found. The treatment “reduced attack rates, improved quality of life, and was generally well tolerated,”…